The MOTION STUDY. Current work involves a project with Prof Carding at UEA to investigate the role of the gut microbiome with the development of dementia. We can measure the neural layers in the retina very accurately to give a proxy measure of the progression or development of dementia. We also hope to find any correlations between the gut microbiome and the development of age related macular degeneration.
Prof Burton is / has been chief investigator UK on the following studies
2019 Lightsite II (Lumithera) - A study looking at Photobiomodulation using the Valeda system for early Dry ARMD
2019 Panda II (Chengdu) - A study looking at Conbercept vs Aflibercept for wet AMRD
Prof Burton is / has been the Principle Investigator at the James Paget University Hospital on the following studies
2020 Precise study - Working with Moorfields Eye Hospital looking at neural networks to predict the outcomes of wet AMD treatment.
2020 Siren Study National Priority Study looking at COVID swab results and immune response.
2020 RECOVERY-RS Study - National Priority Study looking at different types of respiratory support for COVID-19 patients.
2020 RECOVERY Study - National Priority Study for treatment of COVID-19.
2018 Monarch Study - A study looking at electronic devices and vision monitoring tests to detect recurrence and development of wet ARMD.
2018 Rhine study (Roche) - A study looking at Faricimab vs Aflibercept for diabetic macular oedema
2016 Azure Study - A study looking at different treatment regimes in patients with wet AMD.
2016 Fasbat study- An observational study looking at patients diagnosed with wet Age Related Macular Degeneration (ARMD}.
2016 Star Study - A study looking at the role of radiotherapy in wet ARMD treatment.
2016 Drako Study - An observational study looking at Diabetic maculopathy treated with Aflibercept.
2016 Harrier study - ALCON/Novartis RTH258 Phase III. A study looking at a new anti VEGF drug for the treatment of wet Age Related Macular Degeneration
2015 Edna study- A study looking at early detection of ARMD (Open to recruitment March 2015)
2015 Iriss study- A post market surveillance study looking at long term side efects of Iluvien, a slow release steroid inplant for diabetic retinopathy (Open to recruitment March 2015)
2015 Safari study- A study looking the effects of switching wet ARMD patients from Aflibercept to Lucentis (Open to recruitment Oct 2015)
2015 Candle - A study looking at the effects of a light mask on patients having intravitreal injections of Lucentis for diabetic maculopathy (Open to recruitment March 2015.)
2015 Leavo. (Moorfields)12 patients with Central retinal vein occlusion randomised to three different Anti VEGF treatments. (Open to recruitment March 2015.)
2014 Clarity. (Moorfields)– 12 patients with proliferative diabetic retinopathy randomized to Aflibercept or further laser. (Recruitment completed Nov 2015.)
2014 MEMO – Questionnaire study of patients with Vitreomacular traction. (Completed 2015.)
2013 Octave (Novartis) – A trial comparing two different retreatment regimes in wet ARMD. (Completed 2014)
2013 Burden of care 50 patients recruited (Completed)
2011 Luminous Study (Novartis) - Efficacy and safety of Lucentis for ARMD in UK NHS practice. 316 patients recruited 5 year study. Ends March 2016.
2011 Impact Study - Diabetic retinopathy and co-morbidities study. (Completeted 2011.)
2011 Retinal Diseases Study - Psycho-social impact of intravitreal therapies (Completed 2011.)
2011 Constance Study (Allergan)- Efficacy and Safety of Ozurdex for Retinal Vein Occlusions. (Completed 2014)
2010 Relight Study (Novartis) - Study of dose frequency of Lucentis for Diabetic Macular Oedema. (Completed 2014)